

PUBLICATIONS SVEN MAHNER 2002-2011

- 1) Woelber L, Eulenburg C, Choschzick M, Kruell A, Petersen C, Giesecking F, Jaenicke F, **Mahner S**
Prognostic role of lymph-node metastases in vulvar cancer and implications for adjuvant treatment
Int J Gynecol Cancer 2011 [in press] IF 1.558
- 2) Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu EI, **Mahner S**, Speiser P, Marth C, Zeimet AG, Ulmer H, Zeillinger R, Concin N
 Δ 133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
Br J Cancer. 2011 Oct 18. [Epub ahead of print] IF 4.346
- 3) Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, **Mahner S**
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Ann Oncol. 2011 Oct 5. [Epub ahead of print] IF 6.452
- 4) Rohsbach D, Trillsch F, Regier M, Choschzick M, Kommoss F, Hermsteiner M, Töllner T, Mattner UM, Jaenicke F, **Mahner S**
Malignant Transformation of a Serous Borderline Tumor and Early Metastasis of Associated Low-Grade Serous Carcinoma Detected on Screening Mammography.
J Clin Oncol 2011 Sep 19 [Epub ahead of print] IF 18.970
- 5) Woelber L, Kock L, Giesecking F, Petersen C, Trillsch F, Choschzick M, Jaenicke F, **Mahner S**
Clinical management of primary vulvar cancer
Eur J Cancer. 2011 Oct;47(15):2315-21. IF 4.944
- 6) Marme F, Hielscher T, Hug S, Bondong S, Zeilinger R, Cacsire Castillo-Tong D, Sehouli J, Braicu I, Vergote I, Cadron I, **Mahner S**, Ferschke I, Rom J, Sohn C, Schneeweiss A, Altevogt P
Fibroblast growth factor receptor 4 gene (FGFR 4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer
Int J Cancer 2011 [in press] IF 4.926
- 7) Schwegler J, Schwarz J, Blohme C, Ihnen M, Mahner S, Jaenicke F, Giesecking F, Augustin M, Woelber L
Health-related quality of life and patient-defined benefit of clobetasol 0.05% in women with chronic lichen sclerosus of the vulva
Dermatology 2011 Oct 11 [Epub ahead of print] IF 2.714
- 8) Heitz F, du Bois A, Kurzeder C, Pfisterer J, Barinoff J, Grabowski J, Hilpert F, **Mahner S**, Harter P
Surgery for recurrent ovarian cancer
Womens Health (Lond Engl). 2011 Sep;7(5):529-35.
- 9) Woelber L, Choschzick M, Eulenburg C, Hager M, Jaenicke F, Giesecking F, Kock L, Ihnen M, Petersen C, Schwarz J, **Mahner S**
Prognostic value of the pathological resection margin distance in squamous cell cancer of the vulva.
Ann Surg Oncol 2011 May 19 [Epub ahead of print] IF 4.182
- 10) Mury D, Woelber L, Jung S, Eulenburg C, Choschzick M, Witzel I, Schwarz J, Jaenicke F, **Mahner S**
Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer
J Cancer Res Clin Oncol. 2011 Jul;137(7):1131-7. IF 2.485
- 11) **Kock L, Mahner S**, Choschzick M, Eulenburg C, Milde-Langosch K, Schwarz J, Jaenicke F, Mueller V, Woelber L

Serum Carbonic Anhydrase IX (CAIX) and its prognostic relevance in vulvar cancer
(L.K. and S.M. contributed equally to this work)

Int J Gynecol Cancer 2011 Jan;21(1):141-8 IF 1.558

- 12) Woelber L, Hess S, Bohlken H, Tennstedt P, Eulenburg C, Simon R, Giesking F, Jaenicke F, **Mahner S**, Choschzick M
EGFR gene copy number increase increase in vulvar carcinomas is linked with poor clinical outcome
J Clin Pathol 2011 [in press] IF 2.475
- 13) Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, **Mahner S**, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A.
Prospective Validation Study of a Predictive Score for Operability for Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria and MITO.
Int J Gynecol Cancer 2011 Feb; 21(2): 289-295. IF 1.558
- 14) Woelber L, Kress K, Kersten JF, Choschzick M, Kilic E, Herwig U, Lindner C, Schwarz J, Jaenicke F, **Mahner S**, Milde-Langosch K, Mueller V, Ihnen M
Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer
BMC Cancer 2011 Jan 11;11:12 IF 3.153
- 15) Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, **Mahner S**, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G
Topotecan weekly versus conventional five-day schedule in patients with platinum-resistant ovarian cancer (TOWER). A randomized multi-center phase II trial of the NOGGO Ovarian Cancer Study Group
J Clin Oncol 2011 Jan 10;29(2):242-8. Epub 2010 Nov 29 IF 18.970
- 16) Woelber L, Jung S, Eulenburg C, Mueller V, Schwarz J, Jaenicke F, **Mahner S**
Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer
Eur J Surg Oncol 2010 Jun;36(6):583-8. IF 2.564
- 17) Woelber L, Mueller V, Eulenburg C, Schwarz J, Carney W, Jaenicke F, Milde-Langosch K, **Mahner S**
Serum carbonic anhydrase IX during first-line therapy of ovarian cancer
Gynecol Oncol 2010 May;117(2):183-8. IF 3.733
- 18) Trillsch F, **Mahner S**, Ruetzel JD, Harter P, Ewald-Riegler N, Jaenicke F, du Bois A
Clinical management of borderline ovarian tumors
Expert Rev Anticancer Ther. 10(7), 1115-24 (2010) IF 2.493
- 19) Sehouli J, Pietzner K, Harter P, Muenstedt K, **Mahner S**, Hasenburg A, Camara O, Wimberger P, Boehmer D, Buehling K, Richter R, El Khalfaoui K, Oskay-Ozcelik G
Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study.
Ann Oncol 2010 Nov;21(11):2201-5 IF 5.647
- 20) **Mahner S**, Woelber L, Eulenburg C, Schwarz J, Carney W, Jaenicke F, Milde-Langosch K, Mueller V.
TIMP-1 and VEGF-165 concentration during first-line therapy of ovarian cancer patients
BMC Cancer 2010 Apr 13; 10: 139 IF 2.736
- 21) Choschzick M, Woelber L, Hess S, Eulenburg C, Schwarz J, Simon R, **Mahner S**, Jaenicke F, Müller V
Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases

- Virchows Arch* 2010 May;456(5):483-90. IF 2.305
- 22) Witzel I, Milde-Langosch K, Wirtz RM, Roth C, Ihnen M, **Mahner S**, Eulenburg C, Jaenicke F, Mueller V
Comparison of microarray-based RNA expression with ELISA-based protein determination of Her2, uPA and PAI-1 in tumor tissue of breast cancer patients and relation to outcome
J Cancer Res Clin Oncol 2010 Nov;136(11):1709-18. IF 2.261
- 23) Sehoul J, Camara O, **Mahner S**, Bauknecht T, Lichtenegger W, Runnebaum I, Look K, Jaenicke F, Oskay-Oeczelik G
A phase-I-trial of pemetrexed plus carboplatin in recurrent ovarian cancer
Cancer Chemother Pharmacol 2010 Oct;66(5):861-8. IF 2.654
- 24) Harter P, Hilpert F, **Mahner S**, Heitz F, Pfisterer J, du Bois A
Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs
Expert Rev Anticancer Ther. 2010 Jan;10(1):81-8. IF 2.493
- 25) Dose-Schwarz J, Tiling R, Sassen S, **Mahner S**, Harbeck N, Lebeau A, Brenner W, Schwaiger M, Jaenicke F, Untch M, Avril N
Assessment of residual tumor by FDG-PET, anatomical imaging and clinical examination following primary systemic chemotherapy of locally advanced Breast cancer – A prospective multicenter trial
Br J Cancer 2010 Jan 5; 102(1):35-41 IF 4.346
- 26) Harter P, Hilpert F, **Mahner S**, Kommoss S, Heitz F, Pfisterer J, du Bois A
Prognostic Factors for Complete Debulking in First- and Second-Line Ovarian Cancer
Int J Gynecol Cancer 2009;19: S14-17 IF 2.179
- 27) **Mahner S**, Woelber L, Jung S, Eulenburg C, Ihnen M, Schwarz J, Sehoul J, Jaenicke F
Prognostic Significance of CA-125 in the Management of Patients with Recurrent Epithelial Ovarian Carcinoma Selected for Secondary Cytoreduction.
Anticancer Res 2009 Jul;29(7):2817-21 Volume 29 Issue 9 IF 1.428
- 28) Harter P, Hilpert F, **Mahner S**, Pfisterer J, du Bois A
Neue Perspektiven für die Therapie des Ovarialkarzinoms
Gyn Spectrum 2009 Sep; 3
- 29) Poelcher M, **Mahner S**, Ortmann O, Hilfrich J, Diedrich K, Breitbach GP, Hoess C, Leutner C, Braun M, Moebus V, Karbe I, Stimmler P, Rudlowski C, Schwarz J, Kuhn W
Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer - a prospective multicenter phase II trial
Oncol Rep. 2009 Sep;22(3):605-13. IF 1.588
- 30) Harter P, Hilpert F, **Mahner S**, Kommoss S, Heitz F, du Bois A
Role of cytoreductive surgery in recurrent ovarian cancer
Expert Rev Anticancer Ther. 2009 Jul;9(7):917-22. IF 2.493
- 31) **Hein S, Mahner S**, Tirok C, Loening T, Jaenicke F, Milde-Langosch K
Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines
(S.H. and S.M. contributed equally to this work)
Oncol Rep. 2009 Jul;22(1):177-83. IF 1.588
- 32) **Woelber L, Mahner S**, Voelker K, Eulenburg C, Giesecking F, Choschzick M, Jaenicke F, Schwarz J
Clinico-Pathological Prognostic Factors and Patterns of Recurrence in Vulvar Cancer
(L.W. and S.M. contributed equally to this work)
Anticancer Res 2009 Feb;29(2):545-52. IF 1.428
- 33) Sehoul J, Camara O, Schmidt M; **Mahner S**, Seipelt G, Otremba B, Schmalfeld B, Tesch H, Lorenz-Schlüter C, Oskay-Oeczelik G

- Pegylated liposomal doxorubicin (CAELYX®) in patients with advanced ovarian cancer:
Results of a German Multicenter Observational Study
Cancer Chemother Pharmacol. 2009 Aug;64(3):585-91. IF 2.654
- 34) Dose-Schwarz J, Untch M, Tiling R, Sassen S, **Mahner S**, Kahlert S, Harbeck N, Lebeau A, Brenner W, Schwaiger M, Jaenicke F, Avril N
Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential FDG-PET Imaging
J Clin Oncol. 2009 Feb 1;27(4):535-41. IF 17.793
- 35) Sehoul J, **Mahner S**, Garbe E, Oskay-Oezcelik G
Elderly patients in gynecologic oncology
CME Prakt Fortbild Gynakol Geburtsmed Gynakol Endokrinol 2008; 4(3): 264–276
- 36) Harter P, Reuss A, Hasenburg A, **Mahner S**, du Bois A
Rezidivoperation beim Ovarialkarzinom
Gyn Spectrum 2008 4: 7
- 37) **Mahner S**, Baasch C, Schwarz J, Hein S, Woelber L, Jaenicke F, Milde-Langosch K
C-Fos Expression is a Molecular Predictor of Progression and Survival in Epithelial Ovarian Carcinoma
Br J Cancer 2008 Oct 21;99(8):1269-75 IF 4.346
- 38) **Mahner S**, Schirmacher S, Brenner W, Jenicke L, Habermann CR, Avril N, Dose-Schwarz J
Comparison between positron emission tomography using [18F]fluorodeoxyglucose, conventional imaging and computed tomography for staging of breast cancer
Ann Oncol. 2008 Jul; 19(7):1249-54 IF 5.647
- 39) Schwarz J, Schwegler J, Augustin M, Ihnen M, **Mahner S**, Woelber L
The Efficacy of Clobetasol 0.05% for Treatment of Vulvar Lichen Sclerosus
Geburtsh Frauenheilk 2008; 68: 615–619 IF 0.354
- 40) Dose-Schwarz J, **Mahner S**, Schirmacher S, Jenicke L, Müller V, Habermann CR, Brenner W
Detection of metastases in breast cancer patients
Nuklearmed.-Nuclear Medicine 2008 47 3: 97-103. IF 1.867
- 41) Ihnen M, **Mahner S**, Jänicke F, Schwarz J
Current treatment options in uterine endometrial stromal sarcoma.
Int J Gynecol Cancer. 2007 Sep-Oct;17(5):957-63. IF 2.179
- 42) **Nakuci E, Mahner S**, DiRenzo J, ElShamy WM
BRCA1-IRIS regulates Cyclin D1 Expression in Breast Cancer Cells
(**E.N. and S.M. contributed equally to this work**)
Exp Cell Res. 2006 Oct 1;312(16):3120-31. IF 3.589
- 43) Ihnen M, **Mahner S**, Schwarz J
Regression of Condylomata Accuminata during pregnancy following systemic therapy with Thuja
Geburtsh Frauenheilk 2006; 66: 179-182. IF 0.354
- 44) Rost D, **Mahner S**, Sugyama Y, Stremmel W
Expression and localization of the multidrug resistance associated protein 3 in rat small and large intestine
Am J Physiol Gastrointest Liver Physiol. 2002 Apr;282(4):G720-6. IF 3.258

PUBLISHED ABSTRACTS SVEN MAHNER 2002-2011 – FIRST OR SENIOR AUTHOR

- 1) **Mahner S**, Zhao L, Eisenhauer E, Vergote I, Jackisch C, Tai DF, Wan Y, Gill J, Hirte H, Lueck HJ, Richter B, Bentley J, Hanker L, Plante M, Kurzeder C, Popkin D, Wagner U, Pfisterer J
Correlation of dose-intensity and efficacy of gemcitabine/carboplatin in platinum-sensitive

recurrent ovarian cancer (PSOC): Subanalysis of the AGO-Ovar 2.5 phase-III-trial
Proceedings of the 17th international meeting of the European Society of Gynecological Oncology (ESGO) 2011 September 11-14, Milan, Italy S1257

- 2) Sehouli J, Harter P, Fuxius S, Hanker LC, Mueller L, Klare P, Heidrich-Lorsbach E, **Mahner S**
Praefferenz – Prospective study of patients choice for oral or intravenous Treosulfan in elderly patients with recurrent ovarian cancer – Interim analysis
The value of common prognostic factors in advanced cancer for node negative disease
Proceedings of the 17th international meeting of the European Society of Gynecological Oncology (ESGO) 2011 September 11-14, Milan, Italy S960
- 3) Woelber L, Eulenburg C, Choschzick M, Rohsbach D, Hager M, Giesecking F, Petersen C, Jaenicke F, **Mahner S**
The value of common prognostic factors in advanced cancer for node negative disease
Proceedings of the 17th international meeting of the European Society of Gynecological Oncology (ESGO) 2011 September 11-14, Milan, Italy S1298
- 4) **Mahner S**, Meier W, du Bois A, Brown C, Lorusso D, Ferrero A, Cretin J, Havsteen H, Bessette P, Angleitner-Boubenizek L, Vergote I, Vasey P, Gebisky V, Slama B, Herrsted J, Kaizer L, Georgoulopoulos A, Reed N, Wagner U
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIg trial
J Clin Oncol 29: 2011 (suppl; abstr 5059)
- 5) Woelber L, Eulenburg C, Choschzick M, Kock L, Hager M, Giesecking F, Petersen C, Jaenicke F, **Mahner S**
Prognostic factors in node-negative vulvar cancer
J Clin Oncol 29: 2011 (suppl; abstr e15514)
- 6) Sehouli J, Schoening EM, **Mahner S**
What do elderly patients prefer? A prospective multicenter study of preference for oral or intravenous Treosulfan in elderly patients with recurrent ovarian cancer
J Oncol Pharm Practice 17 1 2011 (Supplement) CS5
- 7) **Mahner S**, Jaenicke F
CA-125 during follow-up of patients with ovarian cancer – blessing or curse?
Anticancer Res 31: 2011 1957-2016
- 8) **Mahner S**, Choschzick M, Eulenburg C, Hager M, Giesecking F, Schwarz J, Jaenicke F, Woelber L
Number of metastatic lymph nodes and locoregional control in vulvar cancer
Gynecol Oncol 2011; 120 (Suppl 1): S119
- 9) Harter P, Burges A, Kurzeder C, Reuss A, Canzler U, Lueck HJ, Meier W, Solomayer E, Staehle A, du Bois A, Sehouli J, Baumann K, Hanker LC, Wimberger P, Schroeder W, Gropp M, **Mahner S**
Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal gynecologic tumors. A phase 2 trial of the AGO study group
International Gynecologic Cancer Society Biennial Meeting Proceedings 2010, 153
- 10) **Mahner S**, Staehle A, Eulenburg C, Wegscheider K, Reuss A, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J, du Bois A
Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer – analysis of prospective randomized phase 3 trials
International Gynecologic Cancer Society Biennial Meeting Proceedings 2010, 867
- 11) Woelber L, Eulenburg C, Hager M, Choschzick M, Schwarz J, Jaenicke F, Giesecking F, **Mahner S**
Impact of the pathological resection margin distance for disease recurrence in vulvar cancer
International Gynecologic Cancer Society Biennial Meeting Proceedings 2010, 1360

- 12) **Mahner S**, Eulenburg C, Hager M, Choschzick M, Kock L, Jaenicke F, Schwarz J, Giesecking F, Woelber L
Impact of the number of metastatic lymph-nodes for loco-regional control in vulvar cancer
International Gynecologic Cancer Society Biennial Meeting Proceedings 2010, 1046
- 13) Woelber L, Eulenburg C, Hager M, Choschzick M, Schwarz J, Giesecking F, Jaenicke F, **Mahner S**
Importance of the resection margin distance for disease recurrence in vulvar cancer
Eur J Surg Oncol 2010 36 (9): 889
ESSO "Best Poster" Award
- 14) **Mahner S**, du Bois A, Sehoul J, Lorusso D, Marth C, Reuss A, Poelcher M, Kurzeder C, Canzler U, Harter P
Cytoreductive surgery in recurrent ovarian cancer – the DESKTOP series of the AGO Kommission Ovar, AGO study group, NOGGO, MITO and AGO-Austria
Eur J Surg Oncol 2010 36 (9): 816
- 15) **Mahner S**, Harter P, Reuss A, Pfisterer J, Pujade-Lauraine E, Ray-Coquard I, Lueck HJ, Meier W, Kimmig R, du Bois A
Lymphadenectomy in primary advanced ovarian cancer after complete intraabdominal resection or residual disease < 1cm – results of prospectively randomized phase 3 trials
Eur J Surg Oncol 2010 36 (9): 827
Niall O'Higgins "Best Paper Prize" Award
- 16) Mury D, Woelber L, Eulenburg C, Jung S, Mueller V Jaenicke F, **Mahner S**
Prognostic and predictive impact of CA-125 at primary surgery of ovarian cancer patients
Arch Gynecol Obstet 2010 282 (Suppl 1): S263
- 17) Trillsch F, Woelber L, Mury D, Choschzick M, Dowaji J, Jaenicke F, **Mahner S**
Massive ascites associated with borderline ovarian tumor
Arch Gynecol Obstet 2010 282 (Suppl 1): S109
- 18) **Mahner S**, Staehle A, Eulenburg C, Wegscheider K, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J, du Bois A
Timing of first-line chemotherapy after primary surgery in patients with advanced ovarian cancer: analysis of prospective randomized phase 3 trials
Arch Gynecol Obstet 2010 282 (Suppl 1): S50
- 19) **Mahner S**, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J, du Bois A
Prognostic impact of primary surgical outcome on survival after recurrence in patients with advanced ovarian cancer: Analysis of prospective randomized phase III trials.
J Clin Oncol 28:15s, 2010 (suppl; abstr 5100)
- 20) Woelber L, Eulenburg C, Hager M, Choschzick M, Schwarz J, Dowaji J, Giesecking F, Ihnen M, Jaenicke F, **Mahner S**
Prognostic relevance of resection margin distance for loco-regional control in vulvar cancer
J Clin Oncol 28:15s, 2010 (suppl; abstr 5110)
- 21) Woelber L, Eulenburg C, Hager M, Choschzick M, Giesecking F, Mueller V, Mury D, Jaenicke F, Schwarz J, **Mahner S**
Prognostic role of the number of metastatic lymph nodes for loco-regional control in vulvar cancer
Proceedings of the 5th European Congress of the European Federation for Colposcopy and Cervical Pathology May 27-29 2010 1-036
- 22) **Mahner S**, Staehle A, Eulenburg C, Wegscheider K, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J, du Bois A
Optimal timing of first-line chemotherapy after primary surgery in patients with advanced ovarian cancer – Analysis of prospective randomized phase 3 trials
Onkologie 2010; 33(suppl 2): 1-228

- 23) **Mahner S**, Oskay-Oezcelik G, Heidrich-Lorsbach E, Müller L, Fuxius S, Sommer H, Klare P, Belau A, Ullrich D, Heuser T, Jänicke F, Lichtenegger W, Sehouli J
Oral and intravenous treosulfan in heavily pretreated elderly patients with recurrent ovarian cancer. Safety analysis of a prospective multicenter study of the NOGGO
Onkologie 2010; 33(suppl 2): 1-228
- 24) **Mahner S**, du Bois A, Sehouli J, Reuss A, Baumann K, Hanker L, Wimberger P, Schröder W, Gropp M, Harter P.
Combination therapy with pegliposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal gynecologic tumours. A prospective multicenter phase-II trial of the AGO Study Group
Onkologie 2010; 33(suppl 2): 1-228
- 25) **Mahner S**, Reuss A, Pujade-Lauraine, E, Pfisterer J, Du Bois A.
Complete surgical debulking in advanced ovarian carcinoma improves prognosis in any FIGO stage – Analysis of 3126 prospectively randomized patients in AGO-OVAR/GINECO Phase 3 Trials
Int J Gynaecol Obstet 107: S2; 2009 S254
- 26) **Mahner S**, Oskay-Oezcelik G, Heidrich-Lorsbach E, Sehouli J
Safety analysis of oral and intravenous treosulfan in heavily pretreated elderly patients with recurrent ovarian cancer: A prospective multicenter study of the NOGGO
Int J Gynaecol Obstet 107: S2; 2009 S709
- 27) **Mahner S**, Woelber L, Eulenburger C, Schwarz J, Carney W, Milde-Langosch K, Jaenicke F, Mueller V
TIMP-1 and VEGF Serum Concentration During First-Line Therapy of Ovarian Cancer Patients
Proceedings of the 16th international meeting of the European Society of Gynecological Oncology (ESGO) October 11-14, Belgrad, Serbia S377
- 28) Woelber L, Choschzik M, Hess S, Eulenburger C, Milde-Langosch K, Carney W, Hamer P, Jaenicke F, Schwarz J, Mueller V, **Mahner S**
Prognostic Role of Carbonic Anhydrase IX in Vulvar Cancer
Proceedings of the 16th international meeting of the European Society of Gynecological Oncology (ESGO) October 11-14, Belgrad, Serbia S950
- 29) **Mahner S**, Woelber L, Eulenburger C, Schwarz J, Milde-Langosch K, Mueller V, Jaenicke F
Longitudinale Veränderung und prognostische Bedeutung der Serum-Marker VEGF und TIMP-1 während der Ovariakarzinom Primärtherapie
Arch Gynecol Obstet 2009
- 30) **Mahner S**, Woelber L, Eulenburger C, Schwarz J, Carney W, Jaenicke F, Milde-Langosch K, Mueller V
Serum concentration of TIMP-1 and VEGF-165 during first-line therapy of ovarian cancer patients
Translational Research in Gynecologic Oncology Biennial Meeting: Proceedings; 2009 Sep 10-12; Bergisch-Gladbach, Germany: TraFoKo 2009 S86
- 31) Woelber L, Choschzick M, Hess C, Eulenburger C, Milde-Langosch K, Schwarz J, Carney W, Jaenicke F, Mueller V, **Mahner S**
Prognostic significance of carbonic anhydrase IX in tumor tissue and serum of patients with primary vulvar cancer
Translational Research in Gynecologic Oncology Biennial Meeting: Proceedings; 2009 Sep 10-12; Bergisch-Gladbach, Germany: TraFoKo 2009 S92
Oral Presentation Award “Best of Translational Research”
- 32) **Mahner S**, Woelber L, Schwarz J, Milde-Langosch K, Mueller V, Jaenicke F
Potential Use of VEGF and CAIX as Serum Biomarkers during First-Line Therapy of Ovarian Cancer Patients
Northern German Society of Gynecology and Obstetrics Annual Meeting: Proceedings; 2009 Jun 5-6; Hamburg, Germany: NGGG; 2009. 65

- 33) **Mahner S**, Sehouli J
 What Do Elderly-Patients Prefer? A Prospective Multicenter-Study of Preference for Oral or Intravenous Treosulfan in Elderly-Patients with Recurrent Ovarian Cancer
Northern German Society of Gynecology and Obstetrics Annual Meeting: Proceedings; 2009 Jun 5-6; Hamburg, Germany: NNGG; 2009. 67
- 34) **Mahner S**, Staehle A, Eulenburg C, Wegscheider K, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J, du Bois A
 Prognostic impact of the time interval between primary surgery and start of first-line chemotherapy in patients with advanced ovarian cancer: Analysis of prospective randomized phase III trials.
J Clin Oncol 27:15s, 2009 suppl; abstr 5514
- 35) **Mahner S**, Woelber L, Schwarz J, Carney W, Jaenicke F, Milde-Langosch K, Mueller V
 Changes of VEGF and CAIX serum concentrations during first-line therapy of ovarian cancer patients
ASCO Molecular Markers Meeting Proceedings 2008, 140
- 36) **Mahner S**, Loibl S, Canzler U, Kimmig R, Wollschlaeger K, Hilpert F, du Bois A, Sehouli J, Reinartz S, Reuss A, Pfisterer J
 Anti-idiotypic monoclonal antibody abagovomab in patients with recurrent epithelial ovarian cancer – A phase I/II trial of AGO-OVAR
International Gynecologic Cancer Society Biennial Meeting Proceedings 2008, 1160
- 37) **Mahner S**, Oskay-Oezcelik G, Heidrich-Lorsbach E, Müller L, Fuxius S, Sommer H, Klare P, Belau A, Ullrich D, Heuser T, Jänicke F, Lichtenegger W, Sehouli J
 What Do Elderly-Patients Prefer? A Prospective Multicenter-Study of Preference for Oral or Intravenous Treosulfan in Elderly-Patients with Recurrent Ovarian Cancer
International Gynecologic Cancer Society Biennial Meeting Proceedings 2008, 525
- 38) **Mahner S**, Sehouli J, Wölber L, Jänicke F
 Use of CA-125 in the Management of Ovarian Cancer
Anticancer Res 2008; 28 6B 4033
- 39) **Mahner S**
 Pros and Cons for CA-125 Monitoring in the Follow up Management of Ovarian Cancer Patients
Anticancer Res 2008; 28 5C: 3393
- 40) **Mahner S**, Baasch C, Schwarz J, Woelber L, Jänicke F, Milde-Langosch K
 C-Fos Expression as Predictor of Progression and Survival in Epithelial Ovarian Cancer
Geburtsh Frauenheilk 2008; 68 S1-S194
- 41) **Mahner S**, Baasch C, Woelber L, Beck K, Schwarz J, Jänicke F, Milde-Langosch K
 Prognostic significance of c-Fos expression in epithelial ovarian carcinoma
J Clin Oncol 26: 2008 May 20 suppl; 16540
- 42) **Mahner S**, Baasch C, Wölber L, Schwarz J, Jänicke F
 Expression der Fos-Transkriptionsfaktoren beim epithelialen Ovarialkarzinom
Northern German Society of Gynecology and Obstetrics Annual Meeting: Proceedings; 2008 Apr 4-5; Hamburg, Germany: NNGG; 2008. 10
- 43) Keller A, Jänicke F, Kilmer H, **Mahner S**
 Pre-in-hospital patient management in the gynaecological oncology: The central role of nursing
Onkologie Volume: 31 P: 196 Suppl.1 Published: Feb 2008
- 44) **Mahner S**, Schirmacher S, Müller V, Habermann C, Brenner W, Dose-Schwarz J
 Detection of distant metastases in breast cancer patients: Comparison between [18F]-fluorodeoxyglucose positron emission tomography and conventional imaging
J Clin Oncol. 2007 ASCO Proceedings Part I. Vol 25, No. 18S, 2007: 1054

- 45) **Mahner S**, Milde-Langosch K, Krenkel S, Schwarz J, Jänicke F, Müller V
A preliminary study of soluble epidermal growth factor receptor (sEGFR) before and during palliative treatment with liposomal doxorubicin in relapsed platinum resistant ovarian cancer
Translational Research in Gynecologic Oncology Biennial Meeting: Proceedings; 2007 May 17-19; Bergisch-Gladbach, Germany: TraFoKo ISBN 978-3-938669-03-7; 2007. 57
- 46) Effenberger K, Alpers I, Lips O, Verpoort K, Müller V, Brandt B, **Mahner S**
Different methods for detection of disseminated tumor cells in peripheral blood of patients with advanced stage ovarian cancer
Translational Research in Gynecologic Oncology Biennial Meeting: Proceedings; 2007 May 17-19; Bergisch-Gladbach, Germany: TraFoKo ISBN 978-3-938669-03-7; 2007. 44
- 47) **Mahner S**, Schirmmacher S, Müller V, Habermann C, Brenner W, Jänicke F, Dose-Schwarz J
Detection of metastatic disease in breast cancer - Comparison between [18F]fluorodeoxyglucose positron emission tomography, computed tomography and conventional imaging
Eur J Cancer 2007 Supplements, Vol 5 No 4, P219
- 48) **Mahner S**, Park TW, Ortmann O, Hilfrich J, Breitbach GP, Höss C, Möbus V, Dietrich K, Thomssen C, Kuhn W
Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer: A randomized multicenter phase II study (PRIMOVAR-1)
Gynecol Oncol 104 (2007) S36–S55
- 49) **Mahner S**, Schirmmacher S, Habermann C, Brenner W, Jänicke F, Schwarz J
Mammakarzinom-Staging: Vergleich zwischen FDG-PET und konventioneller Bildgebung
Arch Gynecol Obstet 2007 Volume 276, Number 4 395-462
- 50) **Mahner S**, Park TW, Ortmann O, Hilfrich J, Breitbach GP, Höss C, Möbus V, Dietrich K, Thomssen C, Schwarz J, Jänicke F, Kuhn W
Neoadjuvant chemotherapy with Carboplatin and Docetaxel in advanced ovarian cancer A randomized multicenter Phase II study (PRIMOVAR)
Int J Gynecol Cancer 16 (2006) (s3), 815–830.
- 51) **Mahner S**, Jung S, Ihnen M, Schwarz J, Jänicke F
Vergleich der Häufigkeiten von Komplikationen bei der Rezidivoperation und Primäroperation von Patientinnen mit fortgeschrittenem Ovarialkarzinom
Geburtsh Frauenheilk 2006; 67 DOI: 10.1055/s-2006-952

PUBLISHED ABSTRACTS SVEN MAHNER 2002-2011 – Co-AUTHOR

- 1) Du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, **Mahner S**, Fotopoulou C, Kommos F, Schmalfeld B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Kommos S, Hauptmann S
Retrospective multicenter outcome survey in borderline ovarian tumors (ROBOT; AGO-OVAR OP.5). A study of the AGO study group
The value of common prognostic factors in advanced cancer for node negative disease
Proceedings of the 17th international meeting of the European Society of Gynecological Oncology (ESGO) 2011 September 11-14, Milan, Italy S510
- 2) Woelber L, **Mahner S**, Eulenburg C, Chekerov R, Sehouli J, Cadron I, Vergote I, Zeimet A, Cacsire-Castillo Tong D, Zeilinger R
Prognostic factors in FIGO IV ovarian cancer – An analysis of the OVCAD consortium
The value of common prognostic factors in advanced cancer for node negative disease
Proceedings of the 17th international meeting of the European Society of Gynecological Oncology (ESGO) 2011 September 11-14, Milan, Italy S1513
- 3) Baumann KH, Pujade-Lauraine E, Jackisch C, Lubbe D, du Bois A, Brown C, Sehouli J, Kreienberg R, Belau A, Burges A, Staehle A, Loibl S, Canzler U, Hasenburg A, Schmalfeld B, **Mahner S**, Wiest W, Le Fur N, Wagner U

Therapy expectations of patients with recurrent platinum-sensitive ovarian cancer – A German substudy of the CALYPSO/AGO-OVAR 2.9 trial
Proceedings of the 17th international meeting of the European Society of Gynecological Oncology (ESGO) 2011 September 11-14, Milan, Italy S151

- 4) Froyman W, Cadron I, Van Gorp T, Daemen A, Braicu I, Sehouli J, **Mahner S**, Speiser P, Hofstetter G, Cacsire-Castillo Tong D, Zeilinger R, Vergote I
Predictive factors for peritoneal carcinomatosis in epithelial ovarian cancer, a prospective OVCAD trial
Proceedings of the 17th international meeting of the European Society of Gynecological Oncology (ESGO) 2011 September 11-14, Milan, Italy S1572
- 5) Pils D, Hager G, Wolf A, Aust S, Grimm C, Speiser P, Sehouli J, Braicu I, Cadron I, Vergote I, **Mahner S**, Cacsire-Castillo-Tong D, Zeilinger R
Validation the impact on outcome of a molecular subtype in epithelial ovarian cancer – A study of the OVCAD consortium
The value of common prognostic factors in advanced cancer for node negative disease
Proceedings of the 17th international meeting of the European Society of Gynecological Oncology (ESGO) 2011 September 11-14, Milan, Italy S973
- 6) Chekerov R, **Mahner S**, Lorenz R, Hilpert F, Harter P, Wagner U, Klare P, Sehouli J
Efficacy and safety of sorafenib added to topotecan in patients with platinum-resistant recurrent ovarian cancer – A NOGGO-AGO intergroup run-in study (TRIAS)
Proceedings of the 17th international meeting of the European Society of Gynecological Oncology (ESGO) 2011 September 11-14, Milan, Italy S1058
- 7) Hanker C, du Bois A, Sehouli J, Reuss A, Baumann K, Wimberger P, Schroeder W, Burges A, Gropp M, Kurzeder C, **Mahner S**, Canzler U, Lueck H, Meier W, Fehm T, Staehle A, Harter P
Pegylated liposomal doxorubicin and carboplatin in gynecologic sarcoma. A phase-II trial of the AGO study group
Proceedings of the 17th international meeting of the European Society of Gynecological Oncology (ESGO) 2011 September 11-14, Milan, Italy S108
- 8) Cadron I, Van Gorp T, Sehouli J, Daemen A, Braicu I, **Mahner S**, Speiser P, Hofstetter G, Cacsire-Castillo Tong D, Zeilinger R, Vergote I
Analysis of clinical predictive factors for platinum resistance in epithelial ovarian cancer, a prospective collected dataset within the OVCAD study
Proceedings of the 17th international meeting of the European Society of Gynecological Oncology (ESGO) 2011 September 11-14, Milan, Italy S1091
- 9) Eulenburg C, **Mahner S**, Staehle A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Wegscheider K, Pfisterer J, du Bois A
A comparison of an individual patient data (IPD) meta-analysis and a literature-based meta-analysis to investigate progression-free survival in ovarian cancer patients
Central European Network Conference 2011 Proceedings, CEN 2011
- 10) Harter P, Canzler U, Lueck H, Reuss A, Meier W, Fehm T, Staehle A, Burges A, Kurzeder C, Sehouli J, Baumann K, Hanker L, Wimberger P, Schroeder W, Gropp M, **Mahner S**, du Bois A
Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group
J Clin Oncol 29: 2011 (suppl; abstr 5093)
- 11) El Khalfaoui K, **Mahner S**, Richter R, Hilpert F, Lorenz R, Harter P, Klare P, Wagner U, Chekerov R, Sehouli J
A randomized, double-blind, placebo-controlled, multicenter phase II study to compare the efficacy and safety of sorafenib added to standard treatment with topotecan to standard treatment alone in patients with platinum-resistant recurrent ovarian cancer (TRIAS): Results of a NOGGO-AGO intergroup pilot-study
J Clin Oncol 29: 2011 (suppl; abstr e15548)
- 12) Pils D, Hager G, Wolf A, Aust S, Grimm C, Speiser P, Sehouli J, Braicu I, Cadron I, Vergote I, **Mahner S**, Cacsire-Castillo Tong D, Zeilinger R

Molekulare Subklassifizierung als unabhängiger Prognosefaktor bei Patientinnen mit Ovarialkarzinom – Eine Studie des OVCAD Konsortiums
Proceedings of the BGGF-OEGGG 05 2011

- 13) Bondong S, Hielscher T, Zeimet A, Zeilinger R, Cadron I, Sehouli J, Vergote I, **Mahner S**, Speiser P, Braicu I, Huszar M, Fogel M, Altevogt P
Soluble L1-CAM in the ascites is a prognostic marker in ovarian cancer
102nd Annual meeting of the American association for cancer research Proceedings 2011, 4723
- 14) Belau AK, Heinrich G, Reinthaller A, Rubio MJ, Staehle A, Sommer H, Petru E, Beltran M, Hilpert F, Canzler U, Oskay-Oeczeli G, **Mahner S**, Sehouli J
Topotecan/carboplatin vs. paclitaxel/carboplatin or gemcitabine/carboplatin or pegliposomal doxorubicin/carboplatin: a planned 200 pts interim safety analysis of the HECTOR study (NOGGO/AGO-OVAR/GEICO/AGO-Austria)
International Gynecologic Cancer Society Biennial Meeting Proceedings 2010, 389
- 15) Oskay-Oeczeli G, Chekerov R, Neubert S, Muenstedt K, Liebrich C, Hanker LC, Lorenz R, Wimberger P, **Mahner S**, Langenberg R, Ulrich U, Aydogdu M, Sehouli J
Final results of a German survey in 676 patients: What do ovarian cancer patients expect from their doctor?
International Gynecologic Cancer Society Biennial Meeting Proceedings 2010, 1092
- 16) Sehouli J, Kraetschell R, **Mahner S**, Camara O, Fotopoulou C
Current status of clinical management in endometrial cancer: A national survey of the north-eastern german society of gynecologic oncology (NOGGO)
International Gynecologic Cancer Society Biennial Meeting Proceedings 2010, 1957
- 17) Fineder L, Dieplinger B, Wietzorrek G, Braicu I, Sehouli J, Cadron I, Vergote I, **Mahner S**, Speiser P, Zeilinger R, Dieplinger H
Why are plasma concentrations of afamin reduced in ovarian cancer?
38th Congress of the international society of oncology and biomarkers Proceedings Munich, Germany, September 2010: ISOBM; 2010. 61
- 18) Duesing N, Schwarz J, Choschzick M, Eulenburg C, **Mahner S**, Jaenicke F, Giesecking F, Woelber L
Observational data of 274 women treated with loop electrosurgical excision procedure (LEEP) for cervical intraepithelial neoplasia (CIN)
Arch Gynecol Obstet 2010 282 (Suppl 1): S186
- 19) Woelber L, **Mahner S**, Eulenburg C, Choschzick M, Hager M, Kock L, Jaenicke F, Schwarz J, Giesecking F
Relevance of the number of metastatic lymph-nodes for disease recurrence in vulvar cancer
Arch Gynecol Obstet 2010 282 (Suppl 1): S194
- 20) Pietzner K, Oskay-Oeczeli G, Harter P, Muenstedt K, **Mahner S**, Hasenburg A, Camara O, Wimberger P, Boehmer D, Buehling K, Richter R, El Khalfaoui K, Sehouli J
Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study
Arch Gynecol Obstet 2010 282 (Suppl 1): S51
- 21) Oskay-Oeczeli G, Neubert S, Muenstedt K, Liebrich C, Hanker LC, Lorenz R, Wimberger P, **Mahner S**, Hindenburg H, Sehouli J
What do primary and recurrent ovarian cancer patients (OC) expect from their doctors? Final results of a German survey in 608 patients
J Clin Oncol 28:15s, 2010 (suppl; abstr 5106)
- 22) Braicu EI, Zeilinger R, Vergote IB, **Mahner S**, Zeimet AG, Cadron I, Castillo-Tong D, Chekerov R, Brandt B, Sehouli J
Use of HE4 expression in plasma to predict operative outcome in patients with ovarian cancer
J Clin Oncol 28:15s, 2010 (suppl; abstr 5022)

- 23) Belau A, Canzler U, Schröder W, Richter B, Seifert B, Liebrich W, Uleer C, Krauß T, **Mahner S**, Hilpert F
A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALY PSO study of the Gynecologic Cancer Intergroup (GCIg).
Northern German Society of Gynecology and Obstetrics Annual Meeting: Proceedings; 2010 Jun 18-19; Schwerin, Germany: NGGG; 2010. 38
- 24) Kranzow M, **Mahner S**, Thill M, Hilpert F
Stellenwert der Lymphonodektomie beim fortgeschrittenen Ovarialkarzinom: eine kombinierte explorative Analyse von drei prospektiv randomisierten AGO-OVAR/GINECO Phase 3 Studien
Northern German Society of Gynecology and Obstetrics Annual Meeting: Proceedings; 2010 Jun 18-19; Schwerin, Germany: NGGG; 2010. 29
- 25) Kuehnle E, **Mahner S**, Thill M, Hilpert F
Komplettes chirurgisches Debulking verbessert die Prognose in allen FIGO-Stadien fortgeschrittener Ovarialkarzinome – Analyse von 3126 prospektiv randomisierten Patientinnen aus AGO-OVAR/GINECO Phase 3 Studien
Northern German Society of Gynecology and Obstetrics Annual Meeting: Proceedings; 2010 Jun 18-19; Schwerin, Germany: NGGG; 2010. 30
- 26) Chekerov R, Cadron I, **Mahner S**, Marth C, Braicu I, Richter R, Speiser P, Cacsire-Castillo Tong D, Zeilinger R, Vergote I, Sehouli J
OVCAD – European Multicenter Prospective Ovarian Cancer Consortium: Analysis of the Patients' Histopathology, Surgery and Chemotherapy
Onkologie 2010; 33(suppl 2): 1-228
- 27) Woelber L, Mueller V, Hess S, Eulenburg C, **Mahner S**, Carney W, Milde-Langosch K, Jänicke F, Schwarz J, Choschzick M
Carbonic Anhydrase IX (CAIX) in tumor tissue and sera of patients with primary vulvar cancer
Onkologie 2010; 33(suppl 2): 1-228
- 28) Cadron I, Daemen A, van Gorp T, Sehouli J, Chekerov R, **Mahner S**, Speiser P, Hofstetter G, Cacsire Castillo-Tong D, Zeilinger R, van de Plas R, Amant F, de Moor B, Moerman P, Waelkens E, Vergote I
Discriminatory Protein Profiles in Ovarian Cancer Tissue of Platinum Resistant vs. Sensitive Patients, a Prospective OVCAD Study
Proceedings of the 16th international meeting of the European Society of Gynecological Oncology (ESGO) October 11-14, Belgrad, Serbia S850
- 29) Sehouli J, Chekerov R, Cadron I, **Mahner S**, Zeimet A, Zeilinger R, Speiser P, Cacsire Castillo-Tong D, Vergote I
OVCAD: European Multicenter Prospective Ovarian Cancer Project – First Presentation of Surgical Aspects
Proceedings of the 16th international meeting of the European Society of Gynecological Oncology (ESGO) October 11-14, Belgrad, Serbia S994
- 30) Oskay-Oezcelik G, du Bois A, Chekerov R, Fasching PA, **Mahner S**, Liebrich C, Glaß A, Muenstedt K, Lichtenegger W, Sehouli J, NOGGO and AGO
Expectations of Ovarian Cancer Patients About CA-125 Monitoring in the Follow-Up. Results From a Multicenter Survey in 1060 Patients
Proceedings of the 16th international meeting of the European Society of Gynecological Oncology (ESGO) October 11-14, Belgrad, Serbia S935
- 31) Sehouli J, Harter P, Reuss A, Hasenburg A, Scambia G, Cibula D, **Mahner S**, Vergote I, Reinthaller A, Burges A, Hanker L, Poelcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A, on behalf of AGO Kommission OVAR: AGO-OVAR, AGO Austria, MITO and NOGGO
Prospective validation of a predictive score for complete tumor resection in recurrent ovarian cancer (ROC): an intergroup study of AGO kommission OVAR, AGO-OVAR, AGO Austria, MITO and NOGGO

- 32) Oskay-Oezcelik G, du Bois A, Fasching PA, **Mahner S**, Liebrich C, Glaß A, Schmidt-Wetzel S, Muenstedt C, Lichtenegger W, Sehouli J
How relevant is the CA-125 monitoring for patients with ovarian cancer in the follow-up? - Results from a multicenter survey in 1060 patients with ovarian cancer
European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 466
- 33) Pietzner K, El Khalfaoui K, Oskay-Oezcelik G, Richter R, Harter P, Münstedt K, **Mahner S**, Hasenburg A, Wimberger P, Sehouli J
Platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study
European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 469
- 34) Woelber L, **Mahner S**, Eulenburg C, Schwarz J, Carney W, Jaenicke F, Milde-Langosch K, Mueller V
Longitudinal changes and prognostic significance of serum carbonic anhydrase IX during first-line therapy of ovarian cancer
Translational Research in Gynecologic Oncology Biennial Meeting: Proceedings; 2009 Sep 10-12; Bergisch-Gladbach, Germany: TraFoKo 2009
- 35) Carney WP, **Mahner S**, Woelber L, Eulenburg C, Jaenicke F, Mueller V, Milde-Langosch K, Schwarz J
VEGF-165 and TIMP-1 as potential serum biomarkers during first-line therapy of ovarian cancer patients
Clinical Chemistry, Vol 55, No. 6, Supplement 2009; A110
- 36) Kühnle E, Hilpert F, **Mahner S**, Pfisterer J, Wagner U, Pujade-Lauraine E
Carboplatin (C)/pegyliertes liposomales Doxorubicin (PLD) vs. Carboplatin/Paclitaxel (P) beim platin-sensitiven Ovariakarzinomrezidiv: Interimsanalyse der Phase III CALYPSO GCIG Intergroup Studie zur Durchführbarkeit, Sicherheit und Verträglichkeit
Northern German Society of Gynecology and Obstetrics Annual Meeting: Proceedings; 2009 Jun 5-6; Hamburg, Germany: NGGG; 2009. 64
- 37) Wölber L, **Mahner S**, Jung S, Eulenburg C, Schwarz J, Jänicke F
Feasibility and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer
Northern German Society of Gynecology and Obstetrics Annual Meeting: Proceedings; 2009 Jun 5-6; Hamburg, Germany: NGGG; 2009. 66
- 38) Pujade-Lauraine E, **Mahner S**, Kaern J, GebSKI V, Heywood N, Vasey P, Reinthaller A, Vergote I, Pignata S, Ferrero A
A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG).
J Clin Oncol 27:18s, 2009 suppl; abstr LBA5509
- 39) Oskay-Oezcelik G, du Bois A, Fasching PA, **Mahner S**, Liebrich C, Glaß A, Schmidt-Wetzel S, Leodolter S, Münstedt K, Lichtenegger W, Sehouli J
What do patients think about CA-125 monitoring in the follow-up? Results from a multicenter trial in 1,060 patients with ovarian cancer
J Clin Oncol 27:15s, 2009 suppl; abstr 5522
- 40) El Khalfaoui K, Oskay-Oezcelik G, Richter R, Pietzner K, Harter P, Münstedt K, **Mahner S**, Hasenburg A, Wimberger P, Sehouli J
Prognostic factors in ovarian cancer patients with brain metastases: Results of a German multicenter study
J Clin Oncol 27, 2009 suppl; abstr 16527
- 41) Hein S, Baasch C, Kanowski C, **Mahner S**, Jänicke F, Milde-Langosch K
Expression of Fos-Transcription Factors in Epithelial Ovarian Carcinoma
International AEK Congress Proceedings 2009

- 42) Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, **Mahner S**, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A
Predictive Factors for Resection in Recurrent Ovarian Cancer (ROC). Intergroup Study of AGO Kommission Ovar, AGO-OVAR, AGO Austria, MITO and NOGGO
International Gynecologic Cancer Society Biennial Meeting Proceedings 2008, 38
- 43) Woelber L, **Mahner S**, Voelker K, Eulenburg C, Giesecking F, Choschzick M, Jaenicke F, Schwarz J
Clinico-pathological prognostic factors and pattern of recurrence in vulvar cancer
International Gynecologic Cancer Society Biennial Meeting Proceedings 2008, 584
- 44) Pölcher M, **Mahner S**, Ortmann O, Hilfrich J, Diedrich K, Breitbach GP, Höß C, Thomssen C, Braun M, Stimmler P, Rudlowski C, Leutner C, Möbus V, Jänicke F, Kuhn W
Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer – a prospective multicenter phase II trial (PRIMOVAR)
International Gynecologic Cancer Society Biennial Meeting Proceedings 2008, 658
- 45) Oskay-Oezcelik G, du Bois A, Fasching P.A., **Mahner S**, Liebrich C, Münstedt K, Sehouli J
Was sind die Erwartungen von Patientinnen mit Ovarialkarzinom an die Nachsorge? Finale Ergebnisse einer deutschlandweiten Umfrage an 1040 Patientinnen zur Nachsorge beim Ovarialkarzinom
Geburtsh Frauenheilk 2008; 68 S1-S194
- 46) Pölcher M, **Mahner S**, Ortmann O, Hilfrich J, Braun M, Kuhn W
Neoadjuvant chemotherapy in patients with advanced ovarian cancer: preoperative response evaluation – Results from a prospective multicenter phase II study
Geburtsh Frauenheilk 2008; 68 S1-S194
- 47) Oskay-Oezcelik G, du Bois A, Fasching PA, Liebrich C, Glass A, Münstedt K, **Mahner S**, Koensgen D, Lichtenegger W, Schmidt-Wetzel S, Sehouli J
What do ovarian cancer patients expect from follow-up? Results of a survey of the NOGGO and AGO in 1015 patients
J Clin Oncol 26: 2008 May 20 suppl; abstr 16501
- 48) Pölcher M, **Mahner S**, Ortmann O, Hilfrich J, Diedrich K, Kuhn W
Neoadjuvant chemotherapy in ovarian cancer – a prospective multicenter phase-II trial
Northern German Society of Gynecology and Obstetrics Annual Meeting: Proceedings; 2008 Apr 4-5; Hamburg, Germany: NGGG; 2008. 65
- 49) Oskay-Oezcelik G, du Bois A, Fasching P.A., **Mahner S**, Pfisterer J, Sehouli J
Was sind die Erwartungen und Wünsche von Patientinnen mit Ovarialkarzinom an die Nachsorge? Ergebnisse einer deutschlandweiten Umfrage an 1015 Patientinnen
Northern German Society of Gynecology and Obstetrics Annual Meeting: Proceedings; 2008 Apr 4-5; Hamburg, Germany: NGGG; 2008. 64
- 50) Wölber L, Völker K, Eulenburg C, **Mahner S**, Silberer H, Schwarz J
Klinische und pathologische Prognosefaktoren des Vulvakarzinoms
Northern German Society of Gynecology and Obstetrics Annual Meeting: Proceedings; 2008 Apr 4-5; Hamburg, Germany: NGGG; 2008. 8
- 51) Marquardt W, Jung S, Wölber L, **Mahner S**, Jänicke F, Schwarz J
Postoperativer Tumorrest als Prognosefaktor für die Rezidivoperation bei Ovarialkarzinom-Patientinnen
Northern German Society of Gynecology and Obstetrics Annual Meeting: Proceedings; 2008 Apr 4-5; Hamburg, Germany: NGGG; 2008. 61
- 52) Schirmacher S, **Mahner S**, Brenner W, Habermann C, Jänicke F, Schwarz J
Vergleich der FDG-PET mit konventioneller Diagnostik zum Nachweis von Fernmetastasen beim Mammakarzinom
Northern German Society of Gynecology and Obstetrics Annual Meeting: Proceedings; 2008 Apr 4-5; Hamburg, Germany: NGGG; 2008. 16

- 53) Polcher M, **Mahner S**, Ortmann O, Hilfrich J, Diedrich K, Breitbach JP, Möbus V, Höß C, Thomssen C, Leutner K, Kuhn W
Residual disease after neoadjuvant chemotherapy and debulking surgery in patients with advanced ovarian cancer (prospective, randomized phase II clinical trial to select primary chemotherapy with carboplatin and docetaxel in patients with advanced ovarian cancer stage FIGO IIIC and IV Primovar)
Onkologie Volume: 31 P: 108-109 Suppl.1 Published: Feb 2008
- 54) Keyver-Paik MD, Polcher M, **Mahner S**, Ortmann O, Hilfrich J, Diedrich K, Breitbach JP, Möbus V, Höß C, Thomssen C, Leutner K, Kuhn W
Response evaluation of neoadjuvant chemotherapy in advanced ovarian cancer patients (prospective, randomized phase II clinical trial to select primary chemotherapy with carboplatin and docetaxel in patients with advanced ovarian cancer stage FIGO IIIC and IV Primovar)
Onkologie Volume: 31 P: 109-119 Suppl.1 Published: Feb 2008
- 55) Pils D, Wolf B, Wittinger M, Reibenwein J, Mayer B, Koensgen D, Mustea A, Cadron I, Van Gorp T, **Mahner S**, Concin N, Cacsire-Castillo Tong D, Zeillinger R, Krainer M
Whole genome screening for epigenetically silenced genes using a panel of epithelial cancer cell lines
American Association for Cancer Research Annual Meeting: Proceedings; 2007 Apr 14-18; Los Angeles, CA. Philadelphia (PA): AACR; 2007. 251
- 56) Ihnen M, **Mahner S**, Schwarz J
Behandlungsstrategien von Condylomata acuminata in der Schwangerschaft: Fallbericht und Literaturstudie
Geburtsh Frauenheilk 2006; 67 DOI: 10.1055/s-2006-952796
- 57) Schwarz J, **Mahner S**, Albrecht C, Ihnen M, Hemminger G, Jänicke F
Prospektive Studie zum Vergleich von FDG-PET mit der konventionellen bildgebenden Diagnostik zum Nachweis residualen Tumorgewebes nach neoadjuvanter Chemotherapie vor einer Operation bei Patientinnen mit lokal fortgeschrittenem Mammakarzinom
Geburtsh Frauenheilk 2006; 67 DOI: 10.1055/s-2006-952840
- 58) Schwarz J, Fuchs L, Ihnen M, **Mahner S**, Jänicke F
Retrospektiver Vergleich des prätherapeutischen Stagings (klinisch, CT, MRT) bezüglich Tumorausdehnung und Nodalstatus mit dem histologischen Stadium bei Patientinnen mit Zervixkarzinom
Geburtsh Frauenheilk 2006; 67 DOI: 10.1055/s-2006-952841

BOOK CONTRIBUTIONS SVEN MAHNER 2002-2011

- 1) **Mahner S**, Greiner R, Jänicke F
Ovarialkarzinom
Interdisziplinäre Entscheidungswege in der Onkologie – Bamberger (Edit) 1. Aufl. 2011
- 2) Harter P, **Mahner S**, Hilpert F
Surgery in Ovarian Cancer
Key Questions in Ovarian Cancer – Poveda A (Edit) 1st Edition 2010
- 3) **Mahner S**, Schwarz J, Jänicke F
Prognosefaktoren des Ovarialkarzinoms
Management des Ovarialkarzinoms – Kreienberg R, Schindelmann S, du Bois A, Pfisterer J (Edit.) 1. Aufl. 2009
- 4) **Mahner S**, Schwarz J, Jänicke F
Früherkennung / Vorsorge / Prophylaxe des Ovarialkarzinoms
Management des Ovarialkarzinoms – Kreienberg R, Schindelmann S, du Bois A, Pfisterer J (Edit.) 1. Aufl. 2009

- 5) Schwarz J, **Mahner S**
Tumorartige Läsionen und Tumoren der Ovarien
Intensivkurs Gynäkologie – Bühling K, Friedmann F 2. Aufl. 2008

- 6) Schwarz J, **Mahner S**, Jänicke F
Krankheiten der Adnexe
Die Gynäkologie – Kaufmann M, Costa SD, Scharl A (Edit.) 2., überarb. Aufl., 2006